Belpointe Asset Management LLC Boosts Stock Position in Stryker Corporation $SYK

Belpointe Asset Management LLC increased its holdings in Stryker Corporation (NYSE:SYK) by 2.0% in the 1st quarter, according to its most recent disclosure with the SEC. The firm owned 1,694 shares of the medical technology company’s stock after acquiring an additional 33 shares during the period. Belpointe Asset Management LLC’s holdings in Stryker were worth $631,000 at the end of the most recent quarter.

A number of other large investors also recently added to or reduced their stakes in the company. Continuum Advisory LLC raised its stake in shares of Stryker by 5.8% in the 1st quarter. Continuum Advisory LLC now owns 532 shares of the medical technology company’s stock valued at $198,000 after purchasing an additional 29 shares in the last quarter. Oakworth Capital Inc. raised its stake in shares of Stryker by 0.5% in the 1st quarter. Oakworth Capital Inc. now owns 6,133 shares of the medical technology company’s stock valued at $2,283,000 after purchasing an additional 29 shares in the last quarter. Strategy Asset Managers LLC raised its stake in shares of Stryker by 1.4% in the 1st quarter. Strategy Asset Managers LLC now owns 2,134 shares of the medical technology company’s stock valued at $794,000 after purchasing an additional 29 shares in the last quarter. Tritonpoint Wealth LLC raised its stake in shares of Stryker by 0.7% in the 1st quarter. Tritonpoint Wealth LLC now owns 4,042 shares of the medical technology company’s stock valued at $1,508,000 after purchasing an additional 30 shares in the last quarter. Finally, Monetary Management Group Inc. raised its stake in shares of Stryker by 0.4% in the 1st quarter. Monetary Management Group Inc. now owns 7,668 shares of the medical technology company’s stock valued at $2,854,000 after purchasing an additional 30 shares in the last quarter. 77.09% of the stock is currently owned by institutional investors and hedge funds.

Stryker Stock Down 1.4%

SYK stock opened at $383.32 on Friday. Stryker Corporation has a 12 month low of $329.16 and a 12 month high of $406.19. The firm has a market cap of $146.55 billion, a PE ratio of 50.77, a P/E/G ratio of 2.80 and a beta of 0.93. The firm has a 50 day simple moving average of $388.98 and a 200 day simple moving average of $379.57. The company has a debt-to-equity ratio of 0.70, a current ratio of 1.78 and a quick ratio of 1.06.

Stryker (NYSE:SYK) last released its earnings results on Thursday, July 31st. The medical technology company reported $3.13 EPS for the quarter, beating the consensus estimate of $3.07 by $0.06. The business had revenue of $6.02 billion during the quarter, compared to analyst estimates of $5.92 billion. Stryker had a net margin of 12.25% and a return on equity of 23.94%. The business’s quarterly revenue was up 11.1% on a year-over-year basis. During the same period in the prior year, the business earned $2.81 earnings per share. Stryker has set its FY 2025 guidance at 13.400-13.600 EPS. Equities research analysts forecast that Stryker Corporation will post 13.47 earnings per share for the current fiscal year.

Stryker Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Friday, October 31st. Investors of record on Tuesday, September 30th will be given a $0.84 dividend. This represents a $3.36 annualized dividend and a dividend yield of 0.9%. The ex-dividend date is Tuesday, September 30th. Stryker’s dividend payout ratio is 44.50%.

Insider Activity at Stryker

In related news, Director Ronda E. Stryker sold 200,000 shares of the company’s stock in a transaction that occurred on Wednesday, August 6th. The shares were sold at an average price of $376.45, for a total value of $75,290,000.00. Following the completion of the sale, the director owned 3,222,108 shares in the company, valued at approximately $1,212,962,556.60. This represents a 5.84% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Viju Menon sold 500 shares of the company’s stock in a transaction that occurred on Monday, August 25th. The shares were sold at an average price of $390.61, for a total transaction of $195,305.00. Following the completion of the sale, the insider owned 12,511 shares of the company’s stock, valued at approximately $4,886,921.71. This trade represents a 3.84% decrease in their position. The disclosure for this sale can be found here. 5.90% of the stock is currently owned by corporate insiders.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently issued reports on SYK shares. Truist Financial set a $415.00 target price on shares of Stryker and gave the company a “hold” rating in a research note on Monday, August 4th. Wall Street Zen upgraded shares of Stryker from a “hold” rating to a “buy” rating in a research note on Friday, July 18th. Needham & Company LLC increased their price objective on shares of Stryker from $442.00 to $448.00 and gave the stock a “buy” rating in a research note on Friday, August 1st. BTIG Research reiterated a “buy” rating on shares of Stryker in a research note on Monday, July 14th. Finally, Citigroup reiterated a “buy” rating and set a $455.00 price objective (up previously from $443.00) on shares of Stryker in a research note on Thursday, May 22nd. Fourteen equities research analysts have rated the stock with a Buy rating and four have issued a Hold rating to the stock. Based on data from MarketBeat, Stryker has an average rating of “Moderate Buy” and a consensus price target of $431.42.

Stryker Company Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.